Last reviewed · How we verify

Hatem AbuHashim — Portfolio Competitive Intelligence Brief

Hatem AbuHashim pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Terconazole Vaginal Suppository Terconazole Vaginal Suppository marketed Azole antifungal Lanosterol 14α-demethylase (CYP51) Infectious Disease
Iron bisglycinate Oral Tablet Iron bisglycinate Oral Tablet phase 3 Iron supplement Iron (Fe2+) for hemoglobin and myoglobin synthesis Hematology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. All India Institute of Medical Sciences · 1 shared drug class
  2. Cardiochirurgia E.H. · 1 shared drug class
  3. Clinica Fabia Mater · 1 shared drug class
  4. Dong-A ST Co., Ltd. · 1 shared drug class
  5. Elion Therapeutics, Inc. · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. Hadassah Medical Organization · 1 shared drug class
  8. Abdelwahed, Mai Mahmoud Mohamed, M.D. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hatem AbuHashim:

Cite this brief

Drug Landscape (2026). Hatem AbuHashim — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hatem-abuhashim. Accessed 2026-05-15.

Related